AICDA and hematopoietic and lymphoid cell neoplasm: Conversely, as expected, the frequency of AID-related mutations was slightly higher in hematological cancers at ~8%, specially for B-cell malignancies, like diffuse large B-cell lymphoma (DLBCL), which showed a 10.9% frequency (Supplementary Fig. 2).